Skye Bioscience Statistics
Total Valuation
Skye Bioscience has a market cap or net worth of $42.64 million. The enterprise value is $7.33 million.
Important Dates
The last earnings date was Monday, November 10, 2025, after market close.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Skye Bioscience has 32.06 million shares outstanding. The number of shares has increased by 35.23% in one year.
| Current Share Class | 32.06M |
| Shares Outstanding | 32.06M |
| Shares Change (YoY) | +35.23% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 1.52% |
| Owned by Institutions (%) | 28.46% |
| Float | 19.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.26 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.77, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.77 |
| Quick Ratio | 4.22 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -94.31% and return on invested capital (ROIC) is -61.77%.
| Return on Equity (ROE) | -94.31% |
| Return on Assets (ROA) | -54.88% |
| Return on Invested Capital (ROIC) | -61.77% |
| Return on Capital Employed (ROCE) | -163.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.20M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Skye Bioscience has paid $5,400 in taxes.
| Income Tax | 5,400 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.38% in the last 52 weeks. The beta is 2.66, so Skye Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 2.66 |
| 52-Week Price Change | -71.38% |
| 50-Day Moving Average | 2.36 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 35.26 |
| Average Volume (20 Days) | 346,498 |
Short Selling Information
The latest short interest is 1.95 million, so 6.09% of the outstanding shares have been sold short.
| Short Interest | 1.95M |
| Short Previous Month | 2.33M |
| Short % of Shares Out | 6.09% |
| Short % of Float | 9.92% |
| Short Ratio (days to cover) | 1.20 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -53.94M |
| Pretax Income | -51.22M |
| Net Income | -51.23M |
| EBITDA | -53.22M |
| EBIT | -53.94M |
| Earnings Per Share (EPS) | -$1.29 |
Full Income StatementBalance Sheet
The company has $35.31 million in cash and $321,845 in debt, giving a net cash position of $34.99 million or $1.09 per share.
| Cash & Cash Equivalents | 35.31M |
| Total Debt | 321,845 |
| Net Cash | 34.99M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 32.84M |
| Book Value Per Share | 1.06 |
| Working Capital | 31.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$41.47 million and capital expenditures -$56,336, giving a free cash flow of -$41.53 million.
| Operating Cash Flow | -41.47M |
| Capital Expenditures | -56,336 |
| Free Cash Flow | -41.53M |
| FCF Per Share | -$1.30 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Skye Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.23% |
| Shareholder Yield | -35.23% |
| Earnings Yield | -121.06% |
| FCF Yield | -98.13% |
Analyst Forecast
The average price target for Skye Bioscience is $14.75, which is 1,009.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.75 |
| Price Target Difference | 1,009.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 31.04% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:250.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:250 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
